Meyers B, Borrego F, Papanicolaou G
Transplant Infectious Diseases, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029-6574, USA.
Liver Transpl. 2001 Aug;7(8):750-1. doi: 10.1053/jlts.2001.26433.
Pneumocystis carinii pneumonia (PCP) is an opportunistic infection associated with increased morbidity and mortality in solid-organ and bone-marrow transplant recipients. Side effects of trimethoprim-sulfamethoxazole (TMP/SMX) are frequent; therefore, we performed a preliminary study using atovaquone suspension, 750 mg once daily, for 1 year for the prevention of PCP in liver transplant recipients intolerant to TMP/SMX therapy. Twenty-eight patients were treated, and data were analyzed for efficacy and toxicity. Adverse events occurred in 14 subjects, mainly related to the gastrointestinal tract. Side effects from TMP/SMX, i.e., rash, completely resolved and bone-marrow suppression improved in 62% of patients. No patients developed Pneumocystis carinii infection. Although a lower dose of atovaquone once daily may be effective in transplant recipients, further studies are necessary to confirm this preliminary observation. Liver Transpl 2001;7:750-751.)
卡氏肺孢子虫肺炎（PCP）是一种机会性感染，在实体器官和骨髓移植受者中与发病率和死亡率增加相关。甲氧苄啶-磺胺甲恶唑（TMP/SMX）的副作用很常见；因此，我们进行了一项初步研究，使用阿托伐醌混悬液，每日一次750毫克，对不耐受TMP/SMX治疗的肝移植受者进行为期1年的PCP预防。28例患者接受了治疗，并对疗效和毒性数据进行了分析。14名受试者出现不良事件，主要与胃肠道有关。TMP/SMX的副作用，即皮疹，完全消退，62%的患者骨髓抑制得到改善。没有患者发生卡氏肺孢子虫感染。虽然每日一次较低剂量的阿托伐醌可能对移植受者有效，但需要进一步研究来证实这一初步观察结果。（《肝脏移植》2001年；7：750 - 751）
